BRNS - CIK 0001828185
The table below shows Barinthus Biotherapeutics plc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $65.86M | $74.27M | $86.26M | $99.12M | - | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $72.66M |
| $86.78M |
| $100.41M |
| $109.88M |
| $134.65M |
| $131.88M |
| Property, plant & equipment | $3.27M | $4.52M | $4.51M | $6.20M | $10.72M | $10.96M |
| Goodwill | - | - | - | - | $12.21M | $12.21M |
| Total assets | $92.14M | $109.20M | $129.56M | $142.00M | $188.69M | $186.75M |
| Accounts payable | $993.00K | $698.00K | $1.80M | $1.36M | $3.08M | $2.56M |
| Total current liabilities | $12.00M | $10.80M | $12.72M | $11.98M | $15.07M | $15.59M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $25.66M | $24.64M | $27.08M | $26.40M | $29.23M | $29.96M |
| Retained earnings | -$309.63M | -$293.00M | -$278.44M | -$257.31M | -$217.12M | -$209.01M |
| Total equity | $66.40M | $84.47M | $102.38M | $115.49M | $159.29M | $156.62M |